title: [Outcome of haploidentical hematopoietic stem cell transplantation for non-Hodgkin lymphoma].
abstract: OBJECTIVE
  To explore the efficacy and safety of haploidentical hematopoietic stem cell transplantation (Haplo- HSCT) for refractory, relapsed or highly aggressive non- Hodgkin lymphoma (NHL) patients.
  
  
  METHODS
  A total of 26 patients with refractory, relapsed or highly aggressive NHL who received Haplo- HSCT from Jan. 2004 to Mar. 2015 were analyzed retrospectively.
  
  
  RESULTS
  Of them, 4 patients had diffuse large B-cell lymphoma (DLBCL), 1 had follicular lymphoma, 5 had B-lymphoblastic lymphoma/leukemia, 9 had T- lymphoblastic lymphoma/leukemia, 1 patient anaplastic large cell lymphoma (ALK-negative), 5 had peripheral T-cell lymphoma (NOS), and 1 had NK/T-cell lymphoma. At the time of initial diagnosis, 6 patients had Ann Arbor stage Ⅲ disease, 20 patients showed stage Ⅳ. At the time of Haplo- HSCT, 7 patients were in the first complete remission (CR1), 4 in the second complete remission (CR2), 7 in partial remission, 1 in stable disease, 7 in progressive disease, and 19 of 26 patients were refractory or relapsed. The neutrophil and platelet counts recovered at 12 (11-17) d and 14 (11-31) d after Haplo- HSCT, respectively. All patients achieved full donor chimerism at 30d after Haplo- HSCT. With a median follow- up of 14 (4- 136) months, 20 cases (76.92%) survived, 15 (57.69%) survived without lymphoma, and 7 (26.92%) relapsed. Conditioning regimen related adverse reactions were all disappeared after treatment. The estimated 2-year recurrence rate after Haplo-HSCT was 42.20%. The estimated 2-year overall survival (OS) and disease-free survival (DFS) rate was 71.60% and 48.90%, respectively. Patients in CR before Haplo- HSCT experienced better 2- year OS (100.0% vs 52.4%, P=0.023) and 2- year DFS (88.9% vs 27.0%, P=0.013).
  
  
  CONCLUSIONS
  Haplo- HSCT may effective and safe for those relapsed, refractory or highly aggressive NHL patients who did not have matched donor nor suitable for autologous HSCT.
authors: Jiangsu Institute of Hematology. The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
authors: T
authors: T
authors: Xu
authors: J
authors: J
authors: Chen
authors: Z M
authors: ZM
authors: Jin
authors: M
authors: M
authors: Miao
authors: C C
authors: CC
authors: Fu
authors: H Y
authors: HY
authors: Qiu
authors: X W
authors: XW
authors: Tang
authors: Y
authors: Y
authors: Han
authors: A N
authors: AN
authors: Sun
authors: D P
authors: DP
authors: Wu
mesh_terms: D018572:Disease-Free Survival; D006239:Haplotypes; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D016399:Lymphoma, T-Cell; D016411:Lymphoma, T-Cell, Peripheral; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma; D012008:Recurrence; D012189:Retrospective Studies; D019172:Transplantation Conditioning; D016896:Treatment Outcome